CPHA Canvax

Summary: The primary objective of this statement is to review the evidence on the efficacy, effectiveness, immunogenicity, safety, and cost-effectiveness of PNEU-C-15 and PNEU-C-20 vaccines and provide recommendations for their use in consideration of the disease burden in Canada among adults for whom pneumococcal vaccination is currently recommended: immunocompetent adults aged 65 and older immunocompetent adults at higher risk of pneumococcal disease (PD), immunocompetent adults residing in long term care facilities (LTCF), immunocompromised adults, including hematopoietic stem cell transplant recipients

Rating See Comments Ratings


Program Planning and Delivery,Program Delivery and Evaluation,Clinics,Vaccine Preventable Diseases,Communicable Diseases,Pneumococcal Disease,Specific Populations,Adults Program Planning and Delivery
Program Delivery and Evaluation
Vaccine Preventable Diseases
Communicable Diseases
Pneumococcal Disease
Specific Populations


Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.

All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.